PriceTargets.com logo

ADC Therapeutics - ADCT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.67
  • Forecasted Upside: 263.04%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.01 As of 12/8/2023 01:00 AM ET
▼ -0.06 (-5.61%)

This chart shows the closing price for ADCT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ADC Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADCT

Analyst Price Target is $3.67
▲ +263.04% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for ADC Therapeutics in the last 3 months. The average price target is $3.67, with a high forecast of $6.00 and a low forecast of $2.00. The average price target represents a 263.04% upside from the last price of $1.01.

This chart shows the closing price for ADCT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 polled investment analysts is to hold stock in ADC Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
6/16/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
9/14/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/13/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
3/13/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
6/11/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
9/9/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/8/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/8/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2023HC WainwrightLower TargetBuy ➝ Buy$12.00 ➝ $3.00Low
11/9/2023TD CowenReiterated RatingOutperform ➝ Market PerformLow
11/8/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$7.00 ➝ $6.00Low
9/19/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00Low
9/12/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$9.00 ➝ $8.00Low
8/10/2023JPMorgan Chase & Co.UpgradeUnderweight ➝ NeutralLow
8/9/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$10.00 ➝ $9.00Low
7/25/2023HC WainwrightReiterated RatingBuy ➝ Buy$12.00Low
7/11/2023Morgan StanleyLower Target$5.00 ➝ $2.00Low
6/20/2023HC WainwrightLower Target$20.00 ➝ $12.00Low
4/24/2023Bank of AmericaDowngradeNeutral ➝ UnderperformLow
2/13/2023Royal Bank of CanadaLower TargetOutperform$18.00 ➝ $12.00Low
1/24/2023Morgan StanleyLower TargetEqual Weight$7.00 ➝ $5.00Low
1/4/2023HC WainwrightLower TargetBuy$21.00 ➝ $20.00Low
12/6/2022Capital One FinancialInitiated CoverageOverweight$12.00Low
11/14/2022Morgan StanleyLower TargetEqual Weight$11.00 ➝ $7.00Low
11/9/2022Royal Bank of CanadaLower TargetOutperform$25.00 ➝ $20.00Low
11/8/2022Bank of AmericaDowngradeBuy ➝ Neutral$14.00 ➝ $7.00Low
9/21/2022JPMorgan Chase & Co.Initiated CoverageOverweight$5.00Low
9/19/2022HC WainwrightBoost TargetBuy$20.00 ➝ $21.00Low
9/9/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$17.00 ➝ $11.00Low
8/22/2022HC WainwrightLower TargetBuy$44.00 ➝ $20.00Low
7/11/2022HC WainwrightLower TargetBuy$54.00 ➝ $44.00N/A
5/23/2022HC WainwrightReiterated RatingBuy$54.00Low
4/12/2022Morgan StanleyBoost TargetOverweight$29.00 ➝ $30.00High
3/4/2022HC WainwrightLower TargetBuy$55.00 ➝ $54.00High
2/1/2022Morgan StanleyLower TargetOverweight$47.00 ➝ $29.00High
11/8/2021Wolfe ResearchInitiated CoverageOutperform$44.00Low
11/4/2021HC WainwrightReiterated RatingBuyLow
11/3/2021Royal Bank of CanadaBoost TargetOutperform$33.00 ➝ $34.00Medium
9/7/2021Morgan StanleyLower TargetOverweight$51.00 ➝ $47.00Low
8/10/2021HC WainwrightReiterated RatingBuy$55.00Low
8/9/2021Royal Bank of CanadaInitiated CoverageOutperform$33.00High
7/16/2021Morgan StanleyLower TargetOverweight$53.00 ➝ $51.00Low
6/15/2021Cantor FitzgeraldInitiated CoverageOverweight$46.00Medium
5/14/2021HC WainwrightLower TargetBuy$57.00 ➝ $55.00High
5/10/2021Morgan StanleyLower TargetOverweight$55.00 ➝ $53.00High
4/26/2021HC WainwrightBoost TargetBuy$48.00 ➝ $57.00High
3/23/2021Morgan StanleyLower TargetOverweight$56.00 ➝ $55.00Medium
3/19/2021HC WainwrightBoost TargetBuy$47.00 ➝ $48.00High
12/16/2020Morgan StanleyBoost TargetOverweight$52.00 ➝ $56.00Medium
12/2/2020Stifel NicolausInitiated CoverageHold$42.00High
10/29/2020HC WainwrightInitiated CoverageBuy$47.00Low
10/13/2020Morgan StanleyLower TargetOverweight$53.00 ➝ $52.00Low
6/9/2020Morgan StanleyInitiated CoverageOverweight$53.00High
6/9/2020CowenInitiated CoverageOutperformHigh
6/9/2020Bank of AmericaInitiated CoverageBuy$45.00High
(Data available from 12/9/2018 forward)

News Sentiment Rating

0.26 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
5/12/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/11/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/11/2023
  • 9 very positive mentions
  • 21 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
8/10/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/9/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/9/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/8/2023
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/8/2023

Current Sentiment

  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
ADC Therapeutics logo
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBDdimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Read More

Today's Range

Now: $1.01
Low: $0.94
High: $1.13

50 Day Range

MA: $0.77
Low: $0.47
High: $1.13

52 Week Range

Now: $1.01
Low: $0.36
High: $5.75

Volume

436,420 shs

Average Volume

476,153 shs

Market Capitalization

$77.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of ADC Therapeutics?

The following sell-side analysts have issued reports on ADC Therapeutics in the last twelve months: Bank of America Co., HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Royal Bank of Canada, and TD Cowen.
View the latest analyst ratings for ADCT.

What is the current price target for ADC Therapeutics?

3 Wall Street analysts have set twelve-month price targets for ADC Therapeutics in the last year. Their average twelve-month price target is $3.67, suggesting a possible upside of 263.0%. Royal Bank of Canada has the highest price target set, predicting ADCT will reach $6.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $2.00 for ADC Therapeutics in the next year.
View the latest price targets for ADCT.

What is the current consensus analyst rating for ADC Therapeutics?

ADC Therapeutics currently has 1 sell rating, 3 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ADCT, but not buy more shares or sell existing shares.
View the latest ratings for ADCT.

What other companies compete with ADC Therapeutics?

Other companies that are similar to ADC Therapeutics include IO Biotech, Eagle Pharmaceuticals, Viveon Health Acquisition, Shattuck Labs and Relmada Therapeutics. Learn More about companies similar to ADC Therapeutics.

How do I contact ADC Therapeutics' investor relations team?

The company's listed phone number is 41-21-653-0200 and its investor relations email address is [email protected]. The official website for ADC Therapeutics is www.adctherapeutics.com. Learn More about contacing ADC Therapeutics investor relations.